Cardio-oncology Part I: chemotherapy and cardiovascular toxicity

References

• Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012;61(6):1-51
   PubMedGoogle Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758-65
   PubMed Web of Science ®Google Scholar
• Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin – a review. Int J Pharm Sci Rev Res 2013;18(1):80-5
   Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42(18):3127-39
   PubMed Web of Science ®Google Scholar
• Carver JR, Shapiro CL, Ng A, et al. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25(25):3991-4008
   PubMed Web of Science ®Google Scholar
• Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents. Curr Cardiol Rep 2013;15(5):362
   PubMed Web of Science ®Google Scholar
• Chargari C, Kirov KM, Bollet MA, et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev 2011;37(4):321-30
   Google Scholar
• Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res 2009;1(1):8-12
   PubMedGoogle Scholar
• Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007;67(18):8839-46
   PubMed Web of Science ®Google Scholar
• Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102(4):709-18
   PubMed Web of Science ®Google Scholar
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37(4):300-11
   PubMed Web of Science ®Google Scholar
• Hershman DL, Mcbride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse b-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26(19):3159-65
   PubMed Web of Science ®Google Scholar
• Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19(8):817-28
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710-17
   PubMed Web of Science ®Google Scholar
• Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010;174(6):865-9
   Google Scholar
• Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998;16(11):3493-501
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337
   PubMed Web of Science ®Google Scholar
• Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993;50(6):441-4
   Google Scholar
• Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28(3):374-8
   PubMed Web of Science ®Google Scholar
• Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003;65(2):108-12
   PubMed Web of Science ®Google Scholar
• De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10(11):1795-801
   Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy – a survey of 427 patients. Med Sci Monit 2002;8(6):PI51-7
   Google Scholar
• Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997;75(1-2):55-7
   Google Scholar
• Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995;19(2):141-4
   Google Scholar
• Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001;115(3):653-9
   Google Scholar
• Van Besien K, Devine S, Wickrema A, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003;32(5):471-6
   Google Scholar
• Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy – a case report. Angiology 1999;50(12):1021-5
   Google Scholar
• Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141(6):758-63
   PubMed Web of Science ®Google Scholar
• Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989;24(6):395-6
   Google Scholar
• Rowinsky EK, Mcguire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9(9):1704-12
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monogr 1993(15):117-30
   PubMedGoogle Scholar
• Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014;6:CD006242
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 2003;60(15):1531-48
   Google Scholar
• Ferrajoli A, O’brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98(4):773-8
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Massey MR, Baysinger KB, et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail 2007;13(6 Suppl 2):S151
   Google Scholar
• Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 2005;105(10):4148-9
   Google Scholar
• Spigel DR, Greco FA, Waterhouse D, et al. Phase II trial of folfox6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Clin Adv Hematol Oncol 2010;8(7):480-5, 498
   Google Scholar
• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596-604
   PubMedGoogle Scholar
• Aparicio-Gallego G, Afonso-Afonso FJ, Leon-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs 2011;22(1):1-8
   Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
   PubMed Web of Science ®Google Scholar
• Hamnvik O-PR, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015;121(2):311-19
   PubMed Web of Science ®Google Scholar
• Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007;9(4):320-8
   Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16):1232-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28(13):2280-5
   PubMed Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in fcgr2a transgenic mice. J Thromb Haemost 2009;7(1):171-81
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
   Google Scholar
• Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015;112(2):296-305
   PubMed Web of Science ®Google Scholar
• Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30(8):871-7
   PubMed Web of Science ®Google Scholar
• Hong S, Fang W, Liang W, et al. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco Targets Ther 2014;7:1851-67
   PubMed Web of Science ®Google Scholar
• Faruque LI, Lin M, Battistella M, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One 2014;9(7):e101145
   Google Scholar
• Frankfurt O, Licht JD. Ponatinib – a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res 2013;19(21):5828-34
   PubMed Web of Science ®Google Scholar
• Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)all – role of ponatinib. Biologics 2014;8:243-54
   PubMedGoogle Scholar
• Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA 2014;311(4):353-4
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (grid): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302
   PubMed Web of Science ®Google Scholar
• Jurczyszyn A, Legiec W, Helbig G, et al. New drugs in multiple myelopma – role of carfilzomib and pomalidomids. Contemp Oncol (Pozn) 2014;18(1):17-21
   Google Scholar
• Siegel DS. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2013;4(6):354-65
   PubMedGoogle Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98(11):1753-61
   PubMed Web of Science ®Google Scholar
• Lendvai N, Hilden P, Devlin S, et al. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 2014;124(6):899-906
   PubMed Web of Science ®Google Scholar
• Grandin EW, Ky B, Cornell RF, et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015;21(2):138-44
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Joshua D, Moreau P, Orlowski R. Phase 3 study with carfilzomib and dexamethasone versus velcade and dexamethasone for relapsed multiple myeloma patients (endeavor). 2012–2019. Clinical trials.Gov identifier: NCT01568866 Available from: https://clinicaltrials.Gov/ct2/show/NCT01568866
   Google Scholar
• Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291(20):2441-7
   PubMed Web of Science ®Google Scholar
• Ray A, Ray S, Koner BC. Hypertension, cancer and angiogenesis: relevant epidemiological and pharmacological aspects. Indian J Pharmacol 2004;36(6):314-47
   Google Scholar
• Milan A, Puglisi E, Ferrari L, et al. Arterial hypertension and cancer. Int J Cancer 2014;134(10):2269-77
   Google Scholar
• Ketch T, Biaggioni I, Robertson R, Robertson D. Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation 2002;105(21):2518-23
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. editors. SEER Cancer Statistics Review, 975-2011. National Cancer Institute, Bethesda, MD; 2014. Available from: http://seer.cancer.gov/csr/1975_2011/ based on November 2013 SEER data submission, posted to the SEER web site
   Google Scholar